240 related articles for article (PubMed ID: 11775254)
1. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
[TBL] [Abstract][Full Text] [Related]
2. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
3. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Zhao W; Wang H; Wang X; Wu F; Guo W; Qu B; Shen Z; Wang Z
Thromb Res; 2001 May; 102(3):197-204. PubMed ID: 11369412
[TBL] [Abstract][Full Text] [Related]
4. [Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
Zhao W; Wang H; Guo W
Zhonghua Xue Ye Xue Za Zhi; 1998 Sep; 19(9):473-6. PubMed ID: 11189487
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS).
Watanabe R; Murata M; Takayama N; Tokuhira M; Kizaki M; Okamoto S; Kawai Y; Watanabe K; Murakami H; Kikuchi M; Nakamura S; Ikeda Y
Thromb Haemost; 1997 Apr; 77(4):641-5. PubMed ID: 9134635
[TBL] [Abstract][Full Text] [Related]
6. [A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
Wu F; Wang X; Zhao W; Wang H; Shen Z
Zhonghua Nei Ke Za Zhi; 2001 Jan; 40(1):36-9. PubMed ID: 11798557
[TBL] [Abstract][Full Text] [Related]
7. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
8. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Guo W; Wang H; Zhao W
Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
[TBL] [Abstract][Full Text] [Related]
9. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Zhang X; Zhou H; Song S; Qiao Z; Yang L; Hu Y
Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):829-33. PubMed ID: 16206674
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
11. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
Zhu J; Guo WM; Yao YY; Zhao WL; Pan L; Cai X; Ju B; Sun GL; Wang HL; Chen SJ; Chen GQ; Caen J; Chen Z; Wang ZY
Leukemia; 1999 Jul; 13(7):1062-70. PubMed ID: 10400422
[TBL] [Abstract][Full Text] [Related]
12. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Zhang XH; Hu Y; Bao L; Jiang Q; Yang LH; Lu XJ; Hong M; Xia LH; Guo T; Shen GX; Zhu HH; Zhao T; Song SJ
Chin Med J (Engl); 2009 Sep; 122(17):1969-73. PubMed ID: 19781379
[TBL] [Abstract][Full Text] [Related]
14. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
15. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
16. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.
Dombret H; Scrobohaci ML; Ghorra P; Zini JM; Daniel MT; Castaigne S; Degos L
Leukemia; 1993 Jan; 7(1):2-9. PubMed ID: 8418375
[TBL] [Abstract][Full Text] [Related]
17. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
[TBL] [Abstract][Full Text] [Related]
18. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
Tavernier E; Thomas X
Indian J Cancer; 2003; 40(4):140-3. PubMed ID: 14716110
[TBL] [Abstract][Full Text] [Related]
19. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
20. [Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
Guo W; Zhu J; Wang H
Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):453-5. PubMed ID: 11721405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
